QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
N/A | ||||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
||
(Address of Principal Executive Offices) |
(Zip Code) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
The | ||||
The | ||||
one-third of one redeemable warrant |
The |
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company | ||||
Emerging growth company |
Page |
||||||
3 |
||||||
Item 1. |
3 |
|||||
3 |
||||||
4 |
||||||
5 |
||||||
6 |
||||||
7 |
||||||
Item 2. |
20 |
|||||
Item 3. |
23 |
|||||
Item 4. |
23 |
|||||
24 |
||||||
Item 1. |
24 |
|||||
Item 1A. |
24 |
|||||
Item 2. |
24 |
|||||
Item 3. |
24 |
|||||
Item 4. |
24 |
|||||
Item 5. |
24 |
|||||
Item 6. |
24 |
|||||
25 |
September 30, 2021 |
||||
(unaudited) |
||||
Assets: |
||||
Deferred offering costs |
$ | |||
|
|
|||
Total assets |
$ |
|||
|
|
|||
Liabilities and Shareholder’s Equity |
||||
Accrued offering costs and expenses |
$ | |||
|
|
|||
Total current liabilities |
||||
|
|
|||
Commitments and Contingencies (Note 6) |
||||
Shareholder’s Equity: |
||||
Preference shares, $ |
||||
Class A ordinary shares, $ |
||||
Class B ordinary shares, $ (1) |
||||
Additional paid-in capital |
||||
Accumulated deficit |
( |
) | ||
|
|
|||
Total shareholder’s equity |
||||
|
|
|||
Total Liabilities and Shareholder’s Equity |
$ |
|||
|
|
(1) | This number includes up to |
For the period from August 9, 2021 (inception) through September 30, 2021 |
||||
Formation costs |
$ | |||
Net loss |
$ |
( |
) | |
Basic and diluted weighted average Class B ordinary shares outstanding (1) |
||||
Basic and diluted net loss per share |
$ |
( |
) | |
(1) | This number excludes an aggregate of up to |
Class B |
Additional |
Total |
||||||||||||||||||
Ordinary Shares |
Paid-in |
Accumulated |
Shareholder’s |
|||||||||||||||||
Shares (1) |
Amount |
Capital |
Deficit |
Equity |
||||||||||||||||
Balance as of August 9, 2021 (inception) |
$ | $ | $ | $ | ||||||||||||||||
Class B ordinary shares issued to Sponsor |
||||||||||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance as of September 30, 2021 (unaudited) |
$ | $ | $ | ( |
) | $ | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
(1) | This number includes up to |
Cash flows from operating activities: |
||||
Net loss |
$ | ( |
) | |
Adjustments to reconcile net loss to net cash used in operating activities: |
||||
Formation cost paid by Sponsor |
||||
Changes in operating assets and liabilities: |
||||
Accrued expenses |
||||
|
|
|||
Net cash used in operating activities |
||||
|
|
|||
Net change in cash |
$ |
|||
Cash, August 9, 2021 (inception) |
$ |
|||
|
|
|||
Cash, end of the period |
$ |
|||
|
|
|||
Supplemental disclosure of cash flow information: |
||||
Deferred offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares |
$ | |||
|
|
|||
Deferred offering costs included in accrued offerings costs and expenses |
$ | |||
|
|
• | in whole and not in part; |
• | at a price of $ |
• | upon a minimum of “30-day redemption period”; and |
• | if, and only if, the last reported sale price (the “closing price”) of the Class A ordinary shares equals or exceeds $ |
• |
An Underwriting Agreement, dated December 9, 2021, between the Company, UBS Securities LLC and Kempen & Co. USA, Inc. (the “ Underwriting Agreement ”). |
• |
The Amended and Restated Memorandum and Articles of Association of the Company, dated December 9, 2021. |
• |
A Warrant Agreement, dated December 9, 2021, between the Company and Continental Stock Transfer & Trust Company, as warrant agent. |
• |
A Letter Agreement, dated December 9, 2021, between the Company and its officers, directors and the Sponsor. |
• |
An Investment Management Trust Agreement, dated December 9, 2021, between the Company and Continental Stock Transfer & Trust Company, as trustee. |
• |
A Registration and Shareholder Rights Agreement, dated December 9, 2021, among the Company and the Sponsor. |
• |
An Administrative Services Agreement, dated December 9, 2021, between the Company and the Sponsor. |
• |
A Private Placement Warrants Purchase Agreement, dated December 9, 2021, between the Company and the Sponsor. |
• |
Indemnity Agreements, each dated December 9, 2021, between the Company and each of its executive officers and directors. |
• |
A Forward Purchase Agreement, dated December 9, 2021, between the Company and Forbion Growth Sponsor FEAC I B.V. |
• |
A Forward Purchase Agreement, dated December 9, 2021, between the Company and Forbion Growth Sponsor FEAC I B.V. |
101.INS | Inline XBRL Instance Document* | |
101.SCH | Inline XBRL Taxonomy Extension Schema Document* | |
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document* | |
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document* | |
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document* | |
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document* | |
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)* |
* | Filed herewith. |
FORBION EUROPEAN ACQUISITION CORP. | ||||||
Date: January 24, 2022 | By: | /s/ Wouter Joustra | ||||
Name: | Wouter Joustra | |||||
Title: | Director |